Did you mean melanoma ii?
Displaying drugs 626 - 650 of 713 in total
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
RTA 744
RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers. Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current...
Investigational
Bezitramide
Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's , and marketed under the name Burgodin. After cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market.
Bezitramide has never been FDA approved and is currently a schedule...
Experimental
Illicit
Withdrawn
Matched Description: … Bezitramide has never been FDA approved and is currently a schedule II drug. …
Flupirtine
Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
Investigational
Matched Description: … It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment …
EpiVacCorona
EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus . It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575)[L30608, L30613].
Investigational
Matched Description: … It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575 …
CCX915
CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and...
Investigational
Matched Description: … thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II …
ZEN-012
ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.
Investigational
Matched Description: … first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II …
4'-Methylene-5,8,10-trideazaaminopterin
CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier (RFC) system than is Methotrexate. It has been investigated for the treatment of Rheumatoid Arthritis (phase II).
Investigational
Matched Description: … It has been investigated for the treatment of Rheumatoid Arthritis (phase II). …
Recombinant Bacterial ACE2 Receptors-like Enzyme
B38-CAP is structured as a carboxypeptidase and derived from Paenibacillus sp. The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels. It is being investigated for treating hypertension, myocardial fibrosis, and cardiac dysfunction.
Investigational
Matched Description: … B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels. …
Iron polymaltose
Experimental
Genistein
An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines.
Additionally, genistein has antihelmintic activity. It has been...
Investigational
Matched Description: … It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is …
SGN-30
SGN-30 is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared to on normal cells. SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase...
Investigational
Matched Description: … SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. ... shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase II …
IDM-4
IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes. Trials of this drug have most likely...
Investigational
Matched Description: … IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of …
Olcegepant
Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential...
Investigational
Matched Description: … Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that …
Ethylmorphine
A narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and...
Experimental
Illicit
Matched Description: … In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products). …
Malacidin A
Malacidin A, along with DB14052, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria . Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic analysis. While structurally similar to other macrocycle drugs like DB00080 and DB06087, Malacidin A...
Experimental
Malacidin B
Malacidin B, along with DB14051, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria . Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic analysis. While structurally similar to other macrocycle drugs like DB00080 and DB06087, Malacidin B...
Experimental
VaxSyn
VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).
Investigational
Umbilical Cord Blood Hematopoietic Stem Cells
The use of umbilical cord blood (UCB) for therapies is advantageous because of its ease of access, non-invasive collection procedures, and more plasticity for multi-differentiation. UCB contains a large source of hematopoietic stem cells (HSCs) that are capable of self-renewal, have increased sensitivity to various factors, and are able to...
Investigational
Matched Description: … Because HUCBC are largely immature, do not express class II HLA antigens, and do not produce as many …
ACR-16
ACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington’s disease, Parkinson’s disease and schizophrenia respectively. ACR-16 is a dopamine stabilizer. ACR-16 is also being...
Investigational
Matched Description: … ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled …
Proscillaridin
Proscillaridin is a cardiac glycoside that is derived from plants of the genus Scilla and in Drimia maritima (Scilla maritima). Studies suggest the potential cytotoxic and anticancer property of proscillaridin, based on evidence of the drug potently disrupting topoisomerase I and II activity at nanomolar drug concentrations and triggering cell...
Experimental
Matched Description: … anticancer property of proscillaridin, based on evidence of the drug potently disrupting topoisomerase I and II …
BNT162b3
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. As such, BNT162b3 has...
Investigational
Matched Description: … As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). …
Displaying drugs 626 - 650 of 713 in total